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Systemic treatment with tumor necrosis factor (TNF) is associated with side-effects, limiting its clinical use 
in the treatment of malignancies. To investigate the feasibility of other routes of administration experi- 
mental and clinical studies were started to establish the toxicity and antitumor activity of TNF after 
intratumoral (i.t.) injection. In a rat model for colon adenocarcinoma, tumor fragments, implanted 
subcutaneously or under the hepatic capsule, were treated with TNF injected i.v. or i.t. A dosage of 
40/~g/kg was lethal when given i.v., but not i.t. Injection of TNF (40 pg//kg) directly into the tumor resulted 
in inhibition of tumor growth in the subcutaneous a well as subhepatic tumor model. A phase I study was 
started in patients with advanced malignancies to determine the toxicity of TNF injected into liver 
metastases. Injection of TNF into liver metastases was accomplished by ultrasonography. A 50 ~ug-dose 
escalating schedule (3 patients/dosage) was chosen, starting at a dose of I00/~g TNF/injection. Up to now, 
12 patients have been treated, the highest dosage of TNF injected being 250 pg. Chills, fever, nausea and 
vomiting were the main side-effects. No significant changes were found in circulatory, hematologic, renal 
and liver parameters. In summary, i.t. administration of TNF is associated with antitumor efficacy in 
experimental models and well-tolerated in man. The antitumor efficacy of TNF i.t. in man awaits 
evaluation in a phase II study. 
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Introduction 
Tumor necrosis factor (TNF) is a protein predomi- 
nantly produced by activated macrophages [1, 2]. 
Originally, TNF was named by its capacity to 
induce hemorrhagic necrosis of animal tumors [3]. 
With the availability of recombinant TNF [4] it 
was found that this cytokine is able to exert a 
broad spectrum of regulatory activities on different 
cell types [5-8, 29] and is involved in toxic and 
lethal effects of septicemia nd endotoxic shock 
[9,101. 
It has been demonstrated in vitro that TNF is 
*Corresponding author. 
cytotoxic to selected tumor-cell lines by interacting 
with specific cell surface receptors that can be 
induced by interferon-gamma [11]. In vivo more 
mechanisms may be involved in the antitumor 
effect of TNF, such as modulation of immune 
functions [1] and vascular endothelium. Recently, 
it was reported that TNF is able to modify the 
hemostatic properties of vascular endothelium in 
such a way that the genesis of thrombi s facilitated 
[12, 13]. Furthermore, it has been demonstrated 
that TNF may be directly toxic to vascular endo- 
thelial cells [14]. Most likely, the sum of all these 
effects results in endothelial esions of tumors 
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vessels with occlusion, diminished tissue perfusion 
and necrosis. However, TNF not only exerts its 
activities on endothelial cells of newly formed 
vessels of tumors, but also on vascular endothelial 
cells of normal tissues within the whole organism. 
This may lead to increased vascular permeability 
with loss of plasma and electrolytes from vessels to 
the extravascular compartment and, subsequently, 
hypotension. Furthermore, a decrease of blood 
pressure may be induced by interleukin-1, a cyto- 
kine that is released by endothelial cells upon 
exposure to TNF [6, 15]. 
Considering the mechanism of toxicity induced 
by systemic TNF administration, other routes or 
methods of administration leading to high concen- 
trations of this cytokine at the site Of the tumor, 
but not in circulation, must be evaluated. We 
initiated the following experimental and clinical 
studies to investigate the toxicity and antitumor 
activity of intratumorally injected TNF. First, a rat 
model was used to study toxic and antiproliferative 
effects of intratumoral (i.t.) injection of recombi- 
nant TNF. Secondly, a phase I study was started in 
patients with therapy-resistant liver metastases to 
establish the toxicity of TNF injected into a tumor. 
The results of these experimental nd clinical stu- 
dies are presented. 
Materials and methods 
Experimental study 
Rats. Male rats of the inbred WAG strain were 
used. The animals were bred under specific path- 
ogen-free conditions and were 10-12 weeks old. 
Tumor. A 1,2-dimethylhydrazine-induced, moder- 
ately differentiated colon adenocarcinoma 
(CC531), transplantable in syngeneic WAG rats, 
was used [7]. The tumor is weakly immunogenic as 
determined by the immunization challenge method 
of Prehn and Main [16]. 
TNF. Recombinant murine TNF (rMuTNF), dem- 
onstrated to be effective in the rat model, was 
kindly provided by Dr Fiers (Ghent, Belgium) 
[17]. The preparation used was over 99% pure, 
containing 72 x 10 6 units per mg protein and less 
than 50 ng endotoxin per mg protein. 
Subcutaneous tumor assay. Tumor cubes of 2 × 
2 mm were implanted in the flank of WAG rats 
anesthesized with ether. Growth was established 
by measuring with calipers the two largest perpen- 
dicular diameters of the subcutaneous tumor. The 
average diameter was taken as measure of tumor 
size. 
Sub hepatic capsule assay (SHCA). Rats were 
anesthesized with ether and a median laparotomy 
was performed. After exposure of the liver a small 
incision was made in its capsule and tumor tissue 
of 6-8 mg was put under the capsule and pushed 
cephalad. After 3 weeks, rats were randomized 
and a second laparotomy was performed; after 
measuring the largest perpendicular diameters of 
the tumors located under the hepatic capsule 
either rMuTNF at a dosage of 40/zg or phosphate 
buffered saline (PBS) at a similar volume was 
injected into the tumors. Eight days later, a third 
laparotomy was performed and tumor size was 
evaluated by measuring the two largest perpen- 
dicular diameters of the subcapsular tumors. 
Experiments. First, toxicity and antitumor activity 
of rMuTNF administered by i.v. injection had to 
be established. Non-tumor bearing rats were tre- 
ated i.v. with rMuTNF. Secondly, the effect of i.t. 
injected rMuTNF was established using the subcu- 
taneous or SHCA tumor assay, rMuTNF at a 
dosage of 40/zg (7.2 × 105U/injection) was in- 
jected into subcutaneous growing CC531 tumor 
parts when they had reached a size of 1 cm in 
diameter. Injection of rMuTNF was repeated 5, 10 
and 15 days later. Each group contained seven 
animals; the experiments were performed twice. 
Three weeks after tumor implantation in the 
SHCA assay a single dose (40/zg) of rMuTNF was 
injected into the subcapsular growing tumors. Ex- 
perimental and control groups contained seven 
animals. 
Statistical analysis. Results were analysed using 
Student's t and Wilcoxon's rank sum test. A 
P-value less than 0.05 was considered to indicate a 
significant difference between parameters. 
Clinical study 
Patients. Informed consent was obtained from 12 
adult patients (four female and eight male). The 
study protocol had been approved by the institu- 
tional ethics committee. Criteria for entry into the 
study included histologically proven liver meta- 
stases refractory to standard anticancer therapy 
with normal renal and hematologic functions. In- 
crease of bilirubin and alkaline phosphatase were 
accepted up to two times normal and not due to 
common bile duct obstruction. Life expectancy had 
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to be more than 3 months, with a performance 
status of 0-2; former chemotherapy, radiotherapy 
or surgery had to be more than 4 weeks ago. 
Exclusion criteria were formed by hemorrhagic 
disease, cardiac disease and abnormal neurologic 
examination. At entry of this study, patients were 
evaluated by medical history, physical examina- 
tion, performance status, coagulation profile, com- 
plete blood cell count, determination of liver renal 
function, and determination of serum electrolytes. 
rTNF. Recombinant human TNF (rTNF; provided 
by Knoll, Ludwigshafen, Germany) had a specific 
activity of 6.63 x 106 U/mg protein. The prepara- 
tion used was more than 99% pure and contained 
less than 10 pg endotoxin per mg protein. 
Experimental design. The phase I protocol in- 
cluded a single i.t. injection of rTNF into a liver 
metastasis by ultrasound guidance. To assess toxi- 
city, rTNF was administered according to a 50/zg 
escalating dose schedule with three patients at 
each dose level. If a patient experienced no serious 
toxic side-effects (defined according to the WHO 
criteria as less than grade 2) the protocol per- 
mitted administration of a second, dose escalating 
TNF injection to the same patient after a period of 
at least 4 weeks. The study was started at a dosage 
of 100 tzg rTNF/injection. All patients received 
Indomethacin (50 mg/supp) 30 min before rTNF 
injection. Laboratory data were obtained before 
and 24-72h after rTNF injection. Vital signs 
(pulse, blood pressure and temperature) were 
monitored hourly during the first day after injec- 
tion and repeated three times daily until the fifth 
day after puncture. Two patients were treated 
twice at different dosages after an interval of 4 
weeks. 
Statistics. Data before and after TNF administra- 
tion were compared using the paired Student's 
Table 1. Mortality due to rMuTNF treatment of rats 
TNF-dose 
(/~g/kg) Route of administration Mortality 
4 i.v.; daily 0/6 
8 i.v.; daily 6/6 
8 i.v.; every other day 1/6 
40 i.v.; single injection 6/6 
40 i.v.; single + Indomethacin 0/6 
40 i.t.; weekly 0/6 
i.t. = intratumoral; i.v. = intravenous. 
t-test. A P-value less than 0.05 was considered to 
indicate a significant difference. 
Results 
Experimental study 
A single i.v. injection of rMuTNF at a dosage of 
40/zg/kg body weight was uniformly lethal to all 
animals within 3-5 h (Table 1). As reported ear- 
lier, animals treated with rMuTNF at this dosage 
became diarrheaic within 1 h and had manifest 
blood loss in their feces [18]. At autopsy a hemor- 
rhagic colitis was found that was mainly restricted 
to the caecum. No other signs of gastro-intestinal 
inflammation were found. A single i.v. injection of 
rMuTNF at a dosage of 8/xg/kg body weight was 
well-tolerated by all animals and could be repeated 
on alternate days without leading to hemorrhagic 
colitis. Dosages of 4/xg/kg could be given daily. 
Pretreatment of the animals with Indomethacin 
(i.p.; 10mg/kg body weight, l h before TNF) 
could abolish the lethal effect of i.v. injection of 
rMuTNF at a dosage of 40/zg/kg. Animals treated 
in this way only developed mild transient diarrhea. 
This combined therapy could be repeated three 
times on alternate days before signs of hemor- 
rhagic colitis were observed by blood loss in feces. 
However, this rMuTNF treatment did lead to 
excessive wasting of up to 25% of the body weight 
within l week. 
In the subcutaneous assay i.t. injection of 
rMuTNF at a dosage of 40/xg/kg was well-toler- 
ated. None of the animals treated with i.t. injec- 
tion of rMuTNF at a dosage of 40/zg/kg showed 
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Figure l. Antitumor activity (+) of rMu~F injected 
into subcutaneous CC531 tumors, compared with con- 
trois (---~--); *P<0.05 according to Wilcoxon's rank 
sum test. 
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blood loss in their feces or developed iarrhea, nor 
had excessive weight loss. 
The antitumor effect of rMuTNF after injection 
into subcutaneous growing CC531 tumors on days 
0, 5, 10 and 15 is shown in Figure 1. It was found 
that rMuTNF inhibited tumor growth significantly. 
At day 25 control tumors had a mean diameter of 
26.0 mm, while rMuTNF-treated tumors showed a 
mean diameter of 19.7 mm. However, the differ- 
ence between both groups was mainly due to 
specific types of necrotic lesions observed in only a 
few of the experimental animals. Not all tumors 
treated with rMuTNF showed the same response 
to treatment. Two of the rMuTNF-treated tumors 
showed hemorrhagic necrosis while others did not. 
In the control group such lesions were never 
observed after i.t. injection of PBS. In the SHCA 
assay i.t. administration of rMuTNF resulted in a 
significant umor growth inhibition (Table 2). Eight 
days after i.t. injection of PBS, respectively 
rMuTNF, five out of seven control tumors had 
progressed compared with only one out of six 
rMuTNF-treated tumors, rMuTNF-treated tumors 
showed significantly more necrotic lesions than 
control tumors. None of the i.t. injected rats had 
Table2. Antitumor activity of rMuTNF injected at a 
dosage of 40/xg into CC531 tumors implanted under the 
hepatic apsule 
Tumor growth (ram) 
rMuTNF -5, -1, 0, 0, 0, 1 
PBS -5, -1, 1, 3, 5, 6, 6 
According to Wilcoxon's rank sum test P < 0.05. 
Table3. Characteristics of patients treated with rTNF 
intratumorally 
Patient Dose Diagnosis Sex/age 
1 100 Colon carcinoma F/54 
2 100 Pancreatic arcinoma M/62 
3 100 Adenocarcinoma F/45" 
4 150 Adenocarcinoma F/45 
5 150 Pancreatic arcinoma M/46 
6 150 Bile duct carcinoma F/44" 
7 200 Colon carcinoma M/46 
8 200 Colon carcinoma M/52 
9 200 Stomach carcinoma M/72 
10 250 Bile duct carcinoma F/44 
11 250 Colon carcinoma M/46 
12 250 Colon carcinoma F/54 
* Patients treated with escalating dosages of rTNF. 
signs of rMuTNF toxicity. One of the experimental 
rats died during the second laparotomy due to 
ether toxicity. 
Clinical study 
Characteristics of the patients tudied are given in 
Table 3; the side-effects observed after rTNF injec- 
tion in Table 4. Nine out of 10 patients became 
febrile, with temperature peaks rising to 39.8°C 
within 1-2 h after i.t. injection of rTNF. Body 
temperature returned to normal values within 
3-4 h. In most patients fever was preceded by 
rigors that were not prevented with Indomethacin. 
Two patients pretreated with Indomethacin deve- 
loped mild chills without fever. Generally, rigors 
started 10-20 min after i.t. injection of rTNF and 
lasted for about 30 min. No relationship was found 
between the dose of rTNF given and the intensity 
of systemic side-effects, including rigors, fever and 
nausea. A fall in blood pressure (not < 90 mmHg) 
requiring volume substitution was observed in one 
patient treated concomitantly with morphine. No 
dose-effect relation was observed between rTNF 
and blood pressure. The patients studied had no 
significant changes of hematologic parameters. In- 
tratumoral injections of rTNF neither had an effect 
on renal function or electrolytes, including sodium 
and potassium, nor on white blood cell count and 
differential. In addition, liver function tests 
showed no significant changes in bilirubin, alkaline 
phosphatase, SGOT, SGPT, y-GT and LDH. At 
follow-up, examinations 24-48 h after rTNF injec- 
tion all laboratory parameters were found un- 
changed when compared with pretreatment values. 
No patient showed a significant weight loss. 
An antitumor effect of rTNF, as measured by 
sonographic ontrol, was not observed in any of 
Table 4. Toxicity of rTNF injected into liver metastases 
Dose (10 6 U)/ in ject ion 0.6 0.9 1.3 1.7 
/xg/injection 100 150 200 250 
Fever (>38°C) 3/3 2/3 3/3 1/3 
Chills 2/3 3/3 3/3 3/3 
Nausea 2/3 2/3 3/3 1/3 
Vomiting 1/3 2/3 1/3 1/3 
Diarrhea 0/3 0/3 0/3 0/3 
Hypotension (< 90 syst) 0/3 0/3 0/3 0/3 
Abnormal iver function* 0/3 0/3 0/3 0/3 
Leukopenia(<3000/mm 3) 0/3 0/3 0/3 0/3 
Thrombocytopenia (< 105/mm 3)0/3 0/3 0/3 0/3 
*Changes in liver enzymes: bilirubin, alkaline phospha- 
tase, SGOT, SGPT, LDH, gamma-GT. 
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the patients treated. However, it should be 
stressed that this study is a phase I trial, intended 
to evaluate the toxicity of rTNF. The diameter of 
the liver metastases treated showed a wide range 
of 2-9 cm, which limits the evaluation of antitu- 
mor responses in these patients. 
Discussion 
In the experimental part of this study rMuTNF 
was found to exert anti tumor activity against a rat 
colon carcinoma when administered i.v. as well as 
directly into the tumor. These results are in agree- 
ment with those of others [19, 20]. In vitro experi- 
ments of the CC531 cell line showed no sensitivity 
for rMuTNF. These findings led to the suggestion 
that indirect mechanisms are responsible for the 
antitumor effects seen in vivo, such as activation 
of immunocompetent cells [21]. The immune sys- 
tem seemed to be also important with regard to 
rMuTNF treatment in our SHCA experiments. 
When animals were treated with cyclosporin A 
prior to and during treatment, rMuTNF had only 
half the growth inhibiting effects as without cyclo- 
sporin treatment (unpublished results). 
The toxic effects of rMuTNF were impressive. 
High dosages of rMuTNF led to death of normal 
WAG rats within several hours. The most striking 
finding at autopsy was a severe hemorrhagic oli- 
tis. The colon and especially the cecum appeared 
to be very sensitive to the toxic effects of 
rMuTNF, and massive necrosis was found in this 
part o f the  intestinal tract. Remarkably, the small 
intestine was not involved. 
Of main interest for the aim of our study was 
the observation that dosages of rMuTNF that 
appeared to be lethal when administered i.v., were 
well-accepted when injected directly into the tu- 
mor. Hemorrhagic olitis, one of the most serious 
side-effects after i.v. injection of rMuTNF, was not 
observed in any of the animals treated by i.t. 
injection of rMuTNF at high dosages. Further- 
more, no site-dependent toxicity was found. As in 
the subcutaneous tumor assay rTNF could be in- 
jected in tumors located in the liver without indu- 
cing toxic side-effects. 
The in vitro and in vivo results with TNF gave 
high expectations for the clinical use in cancer 
patients. However, the clinical results with sys- 
temic application of rTNF are disappointing: toxi- 
city is high and only sporadic tumor responses are 
seen. We conducted this phase I trial to achieve 
maximal ocal concentrations of rTNF at the tumor 
site and at the same time reduce systemic toxicity. 
In the clinical study the feasibility of i.t. injection 
of rTNF into liver metastases was demonstrated. 
The main clinical side-effects were fever and ri- 
gors. Whether these symptoms were caused by 
rTNF itself or other cytokines released by TNF, 
such as interleukin-1 [6], remains to be deter- 
mined. It should be noted that the same flu-like 
symptoms have been reported in studies investiga- 
ting the effects of other cytokines, such as interleu- 
kin-2 [22] and interferon-y [23]. This finding may 
indicate a common pathway responsible for these 
side-effects. In the current study no dose-response 
effect was found with regard to toxicity. Fall in 
blood pressure was observed in one patient reated 
concomitantly with morphine. As both agents can 
induce a decrease of blood pressure and may act 
synergistically, concomitant use should be avoided. 
One patient received an anti-emeticum. Besides 
these two patients other patients were treated only 
with Indomethacin and rTNF. Further evaluation 
of the escalating dose schedule will reveal the 
dose-limiting side-effect of rTNF injected intratu- 
morally into liver metastases. 
Pretreatment with Indomethacin did not com- 
pletely prevent rTNF toxicity, although pretreat- 
ment with this NSAID certainly may have reduced 
side-effects. 
In this study rTNF was injected intratumorally 
into liver metastases to minimize systemic side- 
effects. The preliminary results suggest that this 
route of administration of rTNF into liver metas- 
tases is well-accepted and does not lead to serious 
toxicity as in systemic treatment with rTNF. In 
studies using systemic application of rTNF at dos- 
ages limited by toxicity, antitumor esponses were 
seldom observed [24, 25]. In contrast, studies of 
local application of rTNF reported comparable or 
reduced toxicity [26,27]. Although these were 
phase I trials and therefore no conclusions can be 
drawn on the effectiveness of i.t. injection of 
rTNF, regression of tumor growth was seen. A 
phase II trial of intratumoral application of rTNF 
in patients with Kaposi's sarcoma showed tumor 
regression in 15 of the 16 tumors injected [28]. 
These findings suggest hat the local concentration 
of TNF at the tumor site is of utmost importance, 
while circulating systemic TNF mainly stimulates 
mechanisms leading to side-effects but not playing 
a pivotal role in antitumor activity. Thus, the i.t. 
injection of rTNF into liver metastases, alone or in 
combination with other anticancer egimens may 
offer new perspectives to evaluate the potency of 
TNF in cancer treatment. 
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